|
 |
OmalizumabThis page contains recent news articles, when available, and an overview of Omalizumab but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Omalizumab (when available) Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma. For treatment of asthma caused by allergies Mechanism Of Action: Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils. News Articles on Omalizumab Genentech Inc. (DNA:NYSE) - Jul 21, 2008 The company also commercializes Xolair (omalizumab) for adults and adolescents with asthma; Tarceva (erlotinib) for the treatment of metastatic non-small BusinessWeek Genentech profits up 5%, Avastin/Sutent studies stopped - Jul 15, 2008 As for Genentech’s other treatments, sales of Tarceva (erlotinib) for lung and pancreatic cancers were up 17% to $119 million, while Xolair (omalizumab) for Pharma Times (subscription), Antibody drug cost-effective for allergic asthma - Jun 3, 2008 By Will Boggs, MD NEW YORK (Reuters Health) - The antibody drug omalizumab (Xolair) is cost-effective for treating allergic asthma that has not responded Reuters Study confirms cost-effectiveness of antibody allergy drug - Jun 4, 2008 A review of published research showed that Xolair, an antibody drug also known as omalizumab, is a cost-effective treatment for allergic asthma in patients SmartBrief, Study confirms cost-effectiveness of antibody allergy drug - Jun 4, 2008 A review of published research showed that Xolair, an antibody drug also known as omalizumab, is a cost-effective treatment for allergic asthma in patients SmartBrief, Severe asthma and the omalizumab option - May 19, 2008 Omalizumab is a new option for chronic asthma that acts by binding to and inhibiting the effects of IgE, thereby interfering with one aspect of the asthma 7thSpace Interactive (press release), Update in Asthma 2007 - May 16, 2008 The NAEPP guidelines address two new and important treatment issues in adult asthma: omalizumab (anti-IgE) therapy and the preferred approach to moderate RedOrbit, New Asthma Drug Denied To People With Asthma In Northern Ireland - Apr 10, 2008 The approval of Omalizumab (Xolair) across Northern Ireland and the rest of the UK has been heralded by Asthma UK Northern Ireland as a victory for people Medical News Today (press release), Genentech posts strong if unspectacular first-quarter financials - Apr 11, 2008 Sales of Tarceva (erlotinib) for lung and pancreatic cancers were up 8.8% to $111 million, while Xolair (omalizumab) for severe asthma increased 5.4% to Pharma Times (subscription), Genentech Announces First Quarter 2008 Results - Apr 10, 2008 Genentech announced that the Phase III study sponsored by its collaborator Novartis evaluating Xolair(R) (Omalizumab) for subcutaneous use in patients 6 to FOXBusiness Micromet Announces Feasibility Results From Subcutaneous ... - Apr 14, 2008 The company also noted that the anti-IgE antibody omalizumab for the treatment of asthma could also be successfully converted into a BiTE antibody. RTT News, Micromet Demonstrates That The Antibodies In Commercial Products ... - Apr 14, 2008 Likewise, the anti-IgE antibody omalizumab (Xolair®; Genentech, Novartis) for the treatment of asthma can also be successfully converted into a BiTE ABN Newswire (press release), Injections lessen allergic reactions - Apr 13, 2008 Xolair (omalizumab) is a so-called anti-IgE administered once every two to four weeks by injection. Xolair bonds with circulating IgE and blocks the Daytona Beach News-Journal, Micromet Demonstrates that the - Apr 14, 2008 Likewise, the anti-IgE antibody omalizumab(Xolair®; Genentech, Novartis) for the treatment of asthma can alsobe successfully converted into a BiTE antibody. Ad-Hoc-News (Pressemitteilung), Hurdles to launch mean UK uncompetitive, Novartis chief tells paper - Jan 22, 2008 ...of its recent products – Xolair (omalizumab) for asthma and Lucentis (ranibizumab) for age-related macular degeneration, a common cause of blindness. Pharma Times (subscription), Genentech's big three earners fall short of sales estimates - Jan 15, 2008 Sales of Tarceva (erlotinib) for lung and pancreatic cancers sneaked up 5% to $112 million, while Xolair (omalizumab) for severe asthma increased 3% to $120 Pharma Times (subscription), Taligen Gets $65M Series B for Complement Programs - Feb 2, 2008 Severe asthmatics are often treated with high-dose corticosteroids, although the Immunoglobulin E (IgE) targeted monoclonal antibody Xolair (omalizumab, BioWorld Online, Omalizumab, Inhaled Corticosteroid Combo Decreases Asthma ... - Nov 13, 2007 ...[Presentation title: Addition of Omalizumab to Inhaled Corticosteroids in Patients With Persistent Moderate-Severe Asthma Is Associated With a Decrease in DG News Allergen Immunotherapy Evolves as Faster, Safer and Longer-Lasting ... - Nov 10, 2007 The introduction of Omalizumab, a monoclonal ige molecule with anti-ige properties, has helped define asthma as an ige-mediated disease. Newswise (press release) Research Findings on Allergic Asthma Presented at ACAAI Annual Meeting - Nov 12, 2007 ...“Allergic Bronchopulmonary Aspergillosis Treated Successfully with Omalizumab: Three Case Reports.� (Abstract #18: Nov. 11 at 1:15 pm) – Jennifer S. Collins Newswise (press release) Joseph W. Jackson III -- State Journal - Sep 25, 2007 The guidelines also explain when to use newer medications such as Xolair, an injection drug also known as omalizumab. Another key point is that doctors Wisconsin State Journal, New US guidelines look hard at childhood asthma - Aug 29, 2007 Known generically as omalizumab, Xolair is injected and approved only for people over the age of 12 with severe asthma. Continued Reuters India, NICE Backs Xolair(R)-Delta for Severe, Persistent Allergic Asthma - Aug 31, 2007 Clinicians Welcome Drug Watchdog's Decision to Grant NHS Patients Access to Xolair(R) (Omalizumab) for Severe, Persistent Allergic Asthma. Earthtimes.org New guidelines for childhood asthma recommend inhaled corticosteroids - Aug 30, 2007 The newer drugs help control the immune over-reaction which occurs in severe allergic asthma; drugs such as omalizumab (Xolair), made by Genentech and News-Medical.net, New asthma guidelines seek more patient involvement - Aug 30, 2007 ...the guidelines stress, adding that people aged 12 or older who suffer severe asthma must be given the drug omalizumab, to cope with allergic asthma. Earthtimes.org New Asthma Guidelines Stress Disease Control - Aug 29, 2007 These steps include the addition of the drug omalizumab, a monoclonal antibody that targets immunoglobulin E, which is associated with allergic reactions, Forbes, New asthma guidelines balance risk, control - Aug 29, 2007 Known generically as omalizumab, Xolair is injected and approved only for people over age 12 with severe asthma. Scientific American FACTBOX-Asthma drugs attack from several angles - Aug 29, 2007 ...overproduced during an allergic asthma attack. Known generically as omalizumab, it is injected and approved only for people over the age of 12. Continued Reuters.uk, Novartis unit first to get EU approval for generic epoetin alfa - Sep 3, 2007 ...received a recommendation from the UK’s National Institute for Health and Clinical Excellence for the use of Xolair (omalizumab) on the National Health Pharma Times (subscription), National Asthma Guidelines Updated - Aug 31, 2007 ...as adjunct therapy with inhaled corticosteroids; omalizumab for severe asthma; and albuterol, levalbuterol, and corticosteroids for acute exacerbations. Kansas City infoZine, National Asthma Education and Prevention Program Updates Asthma ... - Aug 30, 2007 ...and cromolyn for long-term control, long-acting β-agonists as adjunct therapy with inhaled corticosteroids, and omalizumab for severe asthma. Medscape (subscription) New Asthma Guidelines Emphasize Disease Control and Patient ... - Aug 30, 2007 ...long-acting beta agonists as adjunctive therapy with inhaled corticosteroids; omalizumab (Xolair) for severe asthma, and on the use of albuterol, MedPage Today, Activities aimed at improving relationships between the estate ... - Aug 30, 2007 Known generically as omalizumab, Xolair is injected and approved only for people over age 12 with severe asthma. (Additional reporting by Julie Steenhuysen Daily Mirror (subscription), Genentech completes $919 million acquisition of Tanox - Aug 3, 2007 Pharma Times (subscription),...and the firm now gets full control of Tanox’s stake in Xolair (omalizumab) for asthma, a drug developed in a three-way collaboration between Genentech, Revised Prescribing Information for Xolair - Jul 10, 2007 Facts and Comparisons,Genentech is informing health care professionals and asthmatic patients that the prescribing information for Xolair (omalizumab) injection has been revised Genentech completes its first-ever acquisition - Aug 2, 2007 BiopharmaReporter.com,This move gives Genentech access to a part of the commercial rights for Xolair (omalizumab), an anti-IgE monoclonal antibody (mAb) for patients with asthma Health Highlights: July 4, 2007 - 05 Jul 2007 Forbes,Labeling on the Genentech asthma medication Xolair (omalizumab) has been updated to include the US Food and Drug Administration's strongest possible "black Black-box warning finalized for asthma drug - Jul 2, 2007 MSNBCXolair, given as an injection and known generically as omalizumab, is approved to treat adults and adolescents age 12 and above for moderate to severe NICE's Recommendation Of Approval For Omalizumab (Xolair) Prompts ... - Jun 16, 2007 Medical News Today (press release),After each of the two previous reviews of Omalizumab by the SMC for use in Scotland, the drug was rejected on health economic grounds. Severe asthma 'wonder drug' gets NICE's recommendation for approval - Jun 15, 2007 Healthcare RepublicOmalizumab was licensed for use in the UK in 2005 and is given as an 'add-on therapy' in a fortnightly injection for people with asthma that is severe, NICE backs NHS care for severe allergic asthma - Jun 19, 2007 Healthcare RepublicPatients with severe allergic asthma could be treated with omalizumab on the NHS, according to NICE. A draft technology appraisal states that omalizumab can Tanox Reports 2007 First Quarter Results - May 10, 2007 PharmaLive.com (press release),Net royalty revenue from sales of Xolair(R) (omalizumab) was $11.0 million for the first quarter of 2007, compared to net Xolair royalty revenue of $8.8 Asthma Medication Could Stop You Cold - Apr 21, 2007 Lawyers and Settlements,XOLAIR, which is the trade name for omalizumab, was approved by the FDA in 2003 to treat adults and adolescents 12 years of age and over with moderate to Genentech earnings soar but Lucentis sales slow down slightly - Apr 12, 2007 Pharma Times (subscription),The arthritis and non-Hodgkin's lymphoma drug Rituxan (rituximab) posted a 12% gain to $535 million, while Xolair (omalizumab) for severe asthma was up 17% Genentech Q1 Profit, Revenue Top Consensus; Sees FY07 EPS Growth ... - Apr 11, 2007 Trading Markets,Xolair also known as Omalizumab was approved by the FDA in June 2003 to treat adults and adolescents with moderate to severe allergy-related asthma, Aerovance Tops Off Series C By Garnering $32M Payout - Mar 27, 2007 BioWorld Online,And while asthma drug Xolair (omalizumab, Genentech Inc. and Novartis AG) inhibits IgE and must be injected, Aerovant inhibits upstream targets IL-4 and Brand Names/Synonyms: Omalizumab is also known by the following brand names and/or synonymsIg gamma-1 chain C region; Xolair (Genentech Inc) Drug Category: Omalizumab is categorized under the following by the FDA: Immunomodulatory Agents; Anti-Asthmatic Agents; unclassified therapeutic agents (92:00.00) Dosage Forms: POWDER FOR SOLUTION Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Humanized anti-IgE antibody : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |